Antifungal therapy: Potential interactions with other classes of drugs - 12/10/17
Abstract |
Combination drug therapy is widely used for the management of many common medical conditions. The concurrent use of more than one drug can significantly alter the therapeutic and side-effect profile of each individual agent. Such drug-drug interactions are generally classified either as pharmacokinetic or pharmacodynamic. Oral agents used for the management of superficial fungal infections can have both types of interactions. This article describes common drug-drug interactions observed with amphotericin B, flucytosine, griseofulvin, ke-toconazole, fluconazole, and itraconazole.
Le texte complet de cet article est disponible en PDF.† | Presented at the “International Summit on Cutaneous Antifungal Therapy” Supported by educational grants from janssen pharmaceutica; Ortho pharmaceutical corporation–Dermatological division; Roerig–A division of pfizer; and sandoz pharmaceuticals corporation |
* | Additional data on fluconazole and itraconazole were added from 1993 issue of the Physician's Desk Reference. |
Vol 31 - N° 3P2
P. S87-S90 - septembre 1994 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?